PODD: Leadership change · Company disclosure

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 24, 2026, the Board of Directors (the "Board") of Insulet Corporation (the "Company") appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky will stand for election by stockholders at the Company’s 2027 Annual Meeting of Stockholders. Mr. Mazelsky has been the Executive Chair of the board of directors of IDEXX Laboratories, Inc. since May 2026. He also served at IDEXX as President and Chief Executive Officer from October 2019 to May 2026, as Interim President and Chief Executive Officer from June 2019 to October 2019, and as Executive Vice President responsible for IDEXX’s North American Companion Animal Group Commercial Organization and key elements of their innovation portfolio from August 2012 to June 2019. From 2010 to 2012, he served as Senior Vice President and General Manager, Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips), where he also held roles of increasing responsibility from 2001 to 2010. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent’s Healthcare Group into Philips, and General Manager of Agilent’s Medical Consumables Business Unit from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. He is currently a member of the board of directors of Dentsply Sirona Inc. Mr. Mazelsky has an M.B.A. from the University of Chicago Booth School of Business and a B.A. in M